Skip to nav Skip to content

Clinical Trial Search

292 Clinical Trials Found

Clinical Trial 21621

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 20413

Phase III Study Of Daratumumab/Rhuph20 (Nsc- 810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC STUDY)
Disease Site: Multiple Myeloma
PI: Nishihori, Taiga

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 21193

Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 22562

A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)
Disease Site: Lung, Non small cell lung cancer
PI: Gray, Jhanelle

Clinical Trial 23142

Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy
Disease Site: Breast
PI: Soliman, Hatem

Clinical Trial 23177

A Phase 3, Open-Label, Randomized Study of Sonrotoclax(BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Disease Site: Chronic Leukemia (CLL, CML), Lymphoid Leukemia
PI: Saeed, Hayder

Clinical Trial 23335

Disease Site: Multiple Myeloma
PI: Nguyen, Nina

Clinical Trial 20870

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Disease Site: Other Female Genital, Ovary
PI: Chern, Jing-Yi

Clinical Trial 21416

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Disease Site: Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21854

Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 22102

A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Disease Site: Breast, Other Female Genital, Ovary
PI: Han, Heather